keyword
MENU ▼
Read by QxMD icon Read
search

RECIST

keyword
https://www.readbyqxmd.com/read/28634515/transarterial-chemoembolization-using-40-%C3%A2%C2%B5m-drug-eluting-beads-for-hepatocellular-carcinoma
#1
Giorgio Greco, Tommaso Cascella, Antonio Facciorusso, Roberto Nani, Rodolfo Lanocita, Carlo Morosi, Marta Vaiani, Giuseppina Calareso, Francesca G Greco, Antonio Ragnanese, Marco A Bongini, Alfonso V Marchianò, Vincenzo Mazzaferro, Carlo Spreafico
AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging...
May 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28625656/semi-automatic-volumetric-measurement-of-response-to-chemotherapy-in-lung-cancer-patients-how-wrong-are-we-using-recist
#2
Vladislav Greenberg, Irina Lazarev, Yigal Frank, Julia Dudnik, Samuel Ariad, Ilan Shelef
OBJECTIVES: Lung cancer typically starts as a near-spherical lesion, but as it grows it may acquire an irregular radiologic formation. RECIST is based on the assumption that tumors are spherical, and consequently, proportional changes of tumor volume and parallel changes in tumor diameter, and vice versa. Hence, a 30% decrease in diameter (2r) implies a 65% decrease of volume, and a 20% increase in diameter implies a 73% increase of volume. MATERIALS AND METHODS: We compared volumetric measurement based on multi-detector CT technology with calculated volume (CV) according to RECIST in a cohort of 43 patients with advanced, non-squamous cell type, lung cancer treated with a combination of platinum and pemetrexed...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28625627/a-multicenter-randomized-phase-3-trial-comparing-fixed-dose-versus-toxicity-adjusted-dose-of-cisplatin-etoposide-in-extensive-small-cell-lung-cancer-sclc-patients-the-small-cell-lung-cancer-toxicity-adjusted-dosing-stad-1-trial
#3
Alessandro Morabito, Gennaro Daniele, Raffaele Costanzo, Adolfo Gino Favaretto, Virgilio Filipazzi, Antonio Rossi, Vittorio Gebbia, Federico Castiglione, Luigi Cavanna, Evaristo Maiello, Claudia Sandomenico, Laura Bonanno, Elena Piazza, Paolo Maione, Maria Carmela Piccirillo, Massimo Di Maio, Gaetano Rocco, Ciro Gallo, Francesco Perrone, Cesare Gridelli
OBJECTIVES: Data supporting the prognostic role of chemotherapy induced haematological toxicity suggest that toxicity-adjusted-dosing (TAD) of chemotherapy might improve treatment efficacy. We tested whether TAD of the cisplatin-etoposide combination might improve the response rate, in previously untreated extensive stage disease (ED)-SCLC patients, as compared with standard fixed-dosing (FD). METHODS: Patients with ED-SCLC were randomized to receive either TAD or FD of cisplatin-etoposide as first-line treatment...
June 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28624974/radiological-response-to-the-locoregional-treatment-in-hepatocellular-carcinoma-recist-mrecist-and-others
#4
REVIEW
Mecit Kantarci, Berhan Pirimoglu
No abstract text is available yet for this article.
June 17, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28624558/safety-and-feasibility-of-electrochemotherapy-in-patients-with-unresectable-colorectal-liver-metastases-a-pilot-study
#5
Laura Coletti, Valentina Battaglia, Paolo De Simone, Laura Turturici, Carlo Bartolozzi, Franco Filipponi
BACKGROUND AND OBJECTIVES: Electrochemotherapy is a novel ablation technique combining chemotherapeutic agents with reversible cell membrane electroporation. Previous experiences have shown its efficacy for cutaneous tumors. Its application for deep-seated malignancies is under investigation. We performed a prospective, pilot study to evaluate the feasibility, safety, and efficacy of intraoperative electrochemotherapy for otherwise unresectable colorectal liver metastases. METHODS: Electrochemotherapy with bleomycin was combined with open liver resection and performed with linear or hexagonal needle electrodes according to an individualized pretreatment plan...
June 14, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28624017/association-of-pharmacokinetic-and-metabolic-parameters-derived-using-simultaneous-pet-mri-initial-findings-and-impact-on-response-evaluation-in-breast-cancer
#6
Amarnath Jena, Sangeeta Taneja, Aru Singh, Pradeep Negi, Shashi Bhushan Mehta, Aashim Ahuja, Manish Singhal, Ramesh Sarin
PURPOSE: To study relationships among pharmacokinetic and (18)F-fluorodeoxyglucose ((18)F-FDG) PET parameters obtained through simultaneous PET/MRI in breast cancer patients and evaluate their combined potential for response evaluation. METHODS: The study included 41 breast cancer patients for correlation study and 9 patients (pre and post therapy) for response evaluation. All patients underwent simultaneous PET/MRI with dedicated breast imaging. Pharmacokinetic parameters and PET parameters for tumor were derived using an in- house developed and vendor provided softwares respectively...
July 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28621236/dynamic-soluble-changes-in-svegfr1-hgf-and-vegf-promote-chemotherapy-and-bevacizumab-resistance-a-prospective-translational-study-in-the-becox-gemcad-09-01-trial
#7
Estela Pineda, A Salud, E Vila-Navarro, M J Safont, Beatriz Llorente, J Aparicio, R Vera, P Escudero, E Casado, C Bosch, U Bohn, R Pérez-Carrión, A Carmona, J R Ayuso, T Ripollés, R Bouzas, M Gironella, X García-Albéniz, J Feliu, J Maurel
Despite initial responsiveness, acquired resistance to both bevacizumab and chemotherapy in metastatic colorectal cancer is universal. We have recently published that in vitro, chronically oxaliplatin resistance upregulates soluble vascular endothelial growth factor receptor 1, downregulates vascular endothelial growth factor, and also promotes c-MET, b-catenin/transcription factor 4, and AKT activation. We tested whether variation in three serum biomarkers such as the natural c-MET ligand (hepatocyte growth factor), soluble vascular endothelial growth factor receptor 1, and vascular endothelial growth factor-A was associated with efficacy in metastatic colorectal cancer patients treated in the prospective BECOX study...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28609363/o6-methylguanine-dna-methyltransferase-status-does-not-predict-response-or-resistance-to-alkylating-agents-in-well-differentiated-pancreatic-neuroendocrine-tumors
#8
Nitya Raj, David S Klimstra, Natally Horvat, Liying Zhang, Joanne F Chou, Marinela Capanu, Olca Basturk, Richard Kinh Gian Do, Peter J Allen, Diane Reidy-Lagunes
OBJECTIVES: Alkylating agents have activity in well-differentiated pancreatic neuroendocrine tumors (WD panNETs). In glioblastoma multiforme, decreased activity of O-methylguanine DNA methyltransferase (MGMT) predicts response; in panNETs, MGMT relevance is unknown. METHODS: We identified patients with WD panNETs treated with alkylating agents, determined best overall response by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, and performed MGMT activity testing...
July 2017: Pancreas
https://www.readbyqxmd.com/read/28609226/phase-ii-trial-of-atezolizumab-as-first-line-or-subsequent-therapy-for-patients-with-programmed-death-ligand-1-selected-advanced-non-small-cell-lung-cancer-birch
#9
Solange Peters, Scott Gettinger, Melissa L Johnson, Pasi A Jänne, Marina C Garassino, Daniel Christoph, Chee Keong Toh, Naiyer A Rizvi, Jamie E Chaft, Enric Carcereny Costa, Jyoti D Patel, Laura Q M Chow, Marianna Koczywas, Cheryl Ho, Martin Früh, Michel van den Heuvel, Jeffrey Rothenstein, Martin Reck, Luis Paz-Ares, Frances A Shepherd, Takayasu Kurata, Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, Alan Sandler, Enriqueta Felip
Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non-small-cell lung cancer (NSCLC) across lines of therapy. Patients were selected on the basis of PD-L1 expression on tumor cells (TC) or tumor-infiltrating immune cells (IC). Patients and Methods Eligible patients had advanced-stage NSCLC, no CNS metastases, and zero to two or more lines of prior chemotherapy. Patients whose tumors expressed PD-L1 using the SP142 immunohistochemistry assay on ≥ 5% of TC or IC (TC2/3 or IC2/3 [TC or IC ≥ 5% PD-L1-expressing cells, respectively]) were enrolled...
June 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28608015/prognostic-impact-of-change-in-the-fibrinogen-and-albumin-score-during-preoperative-treatment-in-esophageal-cancer-patients
#10
Satoru Matsuda, Hiroya Takeuchi, Hirofumi Kawakubo, Kazumasa Fukuda, Rieko Nakamura, Koichi Suda, Norihito Wada, Yuko Kitagawa
BACKGROUND: For resectable advanced esophageal cancer, a transthoracic esophagectomy following preoperative treatment is recognized as one of the standard treatments. Therefore, predictive markers which can be identified before surgery need to be established to identify patients with a poor prognosis. METHODS: We retrospectively reviewed 102 consecutive patients who underwent curative transthoracic esophagectomy following preoperative treatment in our institution between 2004 and 2013...
June 12, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28599887/phase-i-trial-of-cediranib-in-combination-with-cisplatin-and-pemetrexed-in-chemo-naive-patients-with-unresectable-malignant-pleural-mesothelioma-swog-s0905
#11
Anne S Tsao, James Moon, Ignacio I Wistuba, Nicholas J Vogelzang, Gregory P Kalemkerian, Mary W Redman, David R Gandara, Karen Kelly
BACKGROUND: In malignant pleural mesothelioma (MPM), targeting angiogenesis, with cediranib, a vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) inhibitor, may have therapeutic potential. METHODS: S0905 phase I combined cediranib (2 dose cohorts 30 mg and 20 mg daily) with cisplatin-pemetrexed for 6 cycles followed by maintenance cediranib in unresectable chemo-naïve MPM patients of any histologic subtype. The primary endpoint established the MTD in combination with cisplatin-pemetrexed in a dose de-escalation schema...
June 6, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28598685/radioembolization-for-unresectable-intrahepatic-cholangiocarcinoma-review-of-safety-response-evaluation-criteria-in-solid-tumors-1-1-imaging-response-and-survival
#12
Nathaniel C Swinburne, Derek M Biederman, Cecilia Besa, Nora E Tabori, Aaron M Fischman, Rahul S Patel, Francis Scott Nowakowski, Ganesh Gunasekaran, Myron E Schwartz, Robert A Lookstein, Edward Kim
The optimal palliative treatment for unresectable intrahepatic cholangiocarcinoma (ICC) remains controversial. While selective internal radiation therapy (SIRT) using yttrium-90 microspheres is a well-accepted treatment for hepatocellular carcinoma, data related to its use for locally advanced ICC remain relatively scarce. Twenty-nine patients (mean age 66 ± 11 years; 15 female) with unresectable biopsy-proven ICC treated with SIRT between June 2008 and April 2015 were retrospectively evaluated for post-treatment toxicity, overall survival, and imaging response using response evaluation criteria in solid tumors (RECIST) 1...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28598136/early-detection-of-recurrence-or-progression-disease-in-patients-with-ovarian-cancer-after-primary-debulking-surgery-a-diagnostic-challenge-still-unresolved-correlation-between-ct-findings-and-ca-125-levels
#13
Michela Giuliani, Benedetta Gui, Anna L Valentini, Silvia E DI Giovanni, Maura Miccò, Elena Rodolfino, Matteo Falcione, Chiara DE Waure, Eleonora Palluzzi, Vanda Salutari, Giovanni Scambia, Riccardo Manfredi
BACKGROUND: There are no standard approaches for follow up in advanced ovarian cancer (AOC) patients; the aim of this study is to evaluate correlation between Computed Tomography (CT) and CA 125 levels to assess early detection of recurrence or progression disease (PD). METHODS: We included 76 patients with AOC, who had prior debulking surgery, starting first or second line of chemotherapy and underwent follow up CT examinations. Evaluation of tumor response to treatment by imaging was assessed using RECIST 1...
June 9, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28597043/prognostic-factors-in-patients-with-advanced-biliary-tract-cancer-treated-with-first-line-gemcitabine-plus-cisplatin-retrospective-analysis-of-740-patients
#14
Bum Jun Kim, Jaewon Hyung, Changhoon Yoo, Kyu-Pyo Kim, Seong-Joon Park, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Jin-Hong Park, Hyungwoo Cho, Baek-Yeol Ryoo, Heung-Moon Chang
PURPOSE: Biliary tract cancer (BTC) is a heterogeneous group of diseases comprising intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer. Although gemcitabine plus cisplatin (GEMCIS) was established as the standard first-line chemotherapy based on the ABC-02 trial, more data are needed to define the clinical course of BTC and its prognostic factors with the standard GEMCIS treatment. METHODS: Between April 2010 and June 2016, 740 patients with histologically documented cholangiocarcinoma and gallbladder cancer were treated with first-line GEMCIS in Asan Medical Center, Seoul, Korea...
June 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28594258/first-line-chemotherapy-with-pemetrexed-plus-cisplatin-for-malignant-peritoneal-mesothelioma
#15
Eriko Fujimoto, Takashi Kijima, Kozo Kuribayashi, Yoshiki Negi, Shingo Kanemura, Koji Mikami, Hiroshi Doi, Kazuhiro Kitajima, Takashi Nakano
BACKGROUND: Mesothelioma of peritoneal origin has wider variation in treatment outcomes than mesothelioma of pleural origin, likely because peritoneal mesothelioma comprises borderline malignant variants and aggressive malignant peritoneal mesothelioma (MPeM). This study retrospectively evaluates the efficacy of first-line systemic pemetrexed and cisplatin chemotherapy in MPeM. RESEARCH DESIGN AND METHODS: Twenty-four patients with histologically proven MPeM were treated with pemetrexed plus cisplatin as a first-line systemic chemotherapy...
June 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28592616/multicenter-phase-ii-study-of-panitumumab-in-platinum-pretreated-advanced-head-and-neck-squamous-cell-cancer
#16
Marco Siano, Francesca Molinari, Vittoria Martin, Nicolas Mach, Martin Früh, Stefania Freguia, Irene Corradino, Michele Ghielmini, Milo Frattini, Vittoria Espeli
LESSONS LEARNED: Panitumumab shows activity in terms of disease control rate and preventing disease progression but not for tumor shrinkage in head and neck squamous cell cancer for second-line treatment. Epidermal growth factor receptor (EGFR) copy number gain, a property of tumor cells that theoretically could identify patients more likely to experience disease response, was common among patients having disease control.Our trial, given the lower toxicity with an every-2-week schedule, provides guidance for future trials, for example, in combinations of immune therapies and anti-EGFR-antibodies...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28587057/safety-and-efficacy-of-stereotactic-ablative-radiation-therapy-for-renal-cell-carcinoma-extracranial-metastases
#17
Chiachien Jake Wang, Alana Christie, Mu-Han Lin, Matthew Jung, Derek Weix, Lorel Huelsmann, Kristin Kuhn, Jeffrey Meyer, Neil Desai, D W Nathan Kim, Ivan Pedrosa, Vitaly Margulis, Jeffrey Cadeddu, Arthur Sagalowsky, Jeffrey Gahan, Aaron Laine, Xian-Jin Xie, Hak Choy, James Brugarolas, Robert Timmerman, Raquibul Hannan
PURPOSE: Renal cell carcinoma is refractory to conventional radiation therapy but responds to higher doses per fraction. However, the dosimetric data and clinical factors affecting local control (LC) are largely unknown. We aimed to evaluate the safety and efficacy of stereotactic ablative radiation therapy (SAbR) for extracranial renal cell carcinoma metastases. METHODS AND MATERIALS: We reviewed 175 metastatic lesions from 84 patients treated with SAbR between 2005 and 2015...
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28586388/a-prospective-pilot-study-of-genome-wide-exome-and-transcriptome-profiling-in-patients-with-small-cell-lung-cancer-progressing-after-first-line-therapy
#18
Glen J Weiss, Sara A Byron, Jessica Aldrich, Ashish Sangal, Heather Barilla, Jeffrey A Kiefer, John D Carpten, David W Craig, Timothy G Whitsett
BACKGROUND: Small cell lung cancer (SCLC) that has progressed after first-line therapy is an aggressive disease with few effective therapeutic strategies. In this prospective study, we employed next-generation sequencing (NGS) to identify therapeutically actionable alterations to guide treatment for advanced SCLC patients. METHODS: Twelve patients with SCLC were enrolled after failing platinum-based chemotherapy. Following informed consent, genome-wide exome and RNA-sequencing was performed in a CLIA-certified, CAP-accredited environment...
2017: PloS One
https://www.readbyqxmd.com/read/28579151/validation-of-the-association-of-recist-changes-with-survival-in-men-with-metastatic-castration-resistant-prostate-cancer-treated-on-swog-study-s0421
#19
Guru Sonpavde, Gregory R Pond, Melissa Plets, Catherine M Tangen, Maha H A Hussain, Primo N Lara, Amir Goldkorn, Mark G Garzotto, Philip C Mack, Celestia S Higano, Nicholas J Vogelzang, Ian M Thompson, Przemyslaw W Twardowski, Peter J Van Veldhuizen, Neeraj Agarwal, Michael A Carducci, J Paul Monk, David I Quinn
BACKGROUND: Phase 2 trials evaluating new agents for metastatic castration-resistant prostate cancer (mCRPC) have relied on bone scan and prostate-specific antigen changes to assess activity. Given the increasing detection of measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST) changes warrant consideration to evaluate activity. We validated the association of RECIST 1.0 changes with survival in men with mCRPC receiving docetaxel. PATIENTS AND METHODS: Data for men with measurable disease from the Southwest Oncology Group (SWOG) S0421, a phase 3 trial in men with mCRPC receiving docetaxel and prednisone plus placebo or atrasentan, were used...
May 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28578690/evaluation-of-treatment-response-and-resistance-in-metastatic-renal-cell-cancer-mrcc-using-integrated-18-f-fluorodeoxyglucose-18-f-fdg-positron-emission-tomography-magnetic-resonance-imaging-pet-mri-the-remap-study
#20
Christian Kelly-Morland, Sarah Rudman, Paul Nathan, Susan Mallett, Giovanni Montana, Gary Cook, Vicky Goh
BACKGROUND: Tyrosine kinase inhibitors are the first line standard of care for treatment of metastatic renal cell carcinoma (RCC). Accurate response assessment in the setting of antiangiogenic therapies remains suboptimal as standard size-related response criteria do not necessarily accurately reflect clinical benefit, as they may be less pronounced or occur later in therapy than devascularisation. The challenge for imaging is providing timely assessment of disease status allowing therapies to be tailored to ensure ongoing clinical benefit...
June 2, 2017: BMC Cancer
keyword
keyword
18088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"